Sofalcone

DB05197ExperimentalSmall molecule

Sofalcone is a mucosal protective agent that has been reported to inhibit growth of Helicobacter pylori. on adherence, production of vacuolating toxin (VT), and induction of interleukin-8 (IL-8) secretion by...

Mechanism: Sofalcone has been reported to have an anti-bacterial effect on H. pylori and the inhibitory effects against the pathogenic factor of H. pylori in addition to the mucosal protective effect due to the inhibition of prostaglandins degradation enzyme. Sofalcone has a direct bactericidal effect on H pylori, anti-urease activity and reduces the adhesion of this organism to gastric epithelial cells
Curator reviewed
Primary indication: Investigated for use/treatment in gastroenteritis and ulcers.Curator reviewed
Formula / weight: C₂₇H₃₀O₆ · 450.5235 g/mol (avg)

Resolves to

Compound

UNII2B668TJX8ECAS64506-49-6ChEMBLCHEMBL1441961PubChem5282219

Structure

InChIKeyGFWRVVCDTLRWPK-KPKJPENVSA-NSMILESCC(C)=CCOC1=CC=C(\C=C\C(=O)C2=C(OCC(O)=O)C=C(OCC=C(C)C)C=C2)C=C1

Targets

P15428HPGDQ14145KEAP1

What you can answer from here — as of July 03, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with Sofalcone, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account